Clinical Trial Update: A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of duvelisib in participants with refractory indolent non-Hodgkin lymphoma has completed and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: SecuraBio | Conditions: Indolent Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-11-20